Morgan Stanley MSOL ETF listed, US SOL spot ETFs see a single-day total net outflow of 18.0734 million USD
According to Odaily, on July 28th Eastern Time, the Morgan Stanley Solana Trust (ticker MSOL) was officially listed on NYSE Arca, bringing the total number of listed SOL spot ETFs to nine.
According to SoSoValue data, MSOL had zero net inflow on its first day of listing, with a trading volume of 19.03 million US dollars and a total net asset value of 1 million US dollars. MSOL supports a cash subscription/redemption mechanism, has a management fee rate of 0.14%, and plans to support Solana staking yield mechanism.
Yesterday, only the Bitwise Solana Staking ETF (BSOL) saw a net outflow, with a single-day net outflow of 18.0734 million US dollars. The historical total net inflow currently stands at 891 million US dollars.
As of the time of publication, the total net asset value of SOL spot ETFs is 852 million US dollars, with a SOL net asset ratio of 1.99%. The cumulative historical net inflow has reached 1.127 billion US dollars.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
